BRPI0820964A2 - Oxazolidinonas para o tratamento e/ou profilaxia de insuficiência cardíaca - Google Patents

Oxazolidinonas para o tratamento e/ou profilaxia de insuficiência cardíaca

Info

Publication number
BRPI0820964A2
BRPI0820964A2 BRPI0820964-2A BRPI0820964A BRPI0820964A2 BR PI0820964 A2 BRPI0820964 A2 BR PI0820964A2 BR PI0820964 A BRPI0820964 A BR PI0820964A BR PI0820964 A2 BRPI0820964 A2 BR PI0820964A2
Authority
BR
Brazil
Prior art keywords
oxazolidinones
prophylaxis
treatment
heart failure
heart
Prior art date
Application number
BRPI0820964-2A
Other languages
English (en)
Inventor
Harald Kallabis
Wolfgang Thielemann
Elisabeth Perzborn
Susanne Röhrig
Dagmar Kubitza
Theodore Spiro
Lloyd Haskell
Jeet Mahal
Original Assignee
Bayer Schering Pharma Ag
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Janssen Pharmaceutica Nv filed Critical Bayer Schering Pharma Ag
Publication of BRPI0820964A2 publication Critical patent/BRPI0820964A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0820964-2A 2007-12-11 2008-12-03 Oxazolidinonas para o tratamento e/ou profilaxia de insuficiência cardíaca BRPI0820964A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US740607P 2007-12-11 2007-12-11
PCT/EP2008/010211 WO2009074249A1 (en) 2007-12-11 2008-12-03 Oxazolidinones for the treatment and/or prophylaxis of heart failure

Publications (1)

Publication Number Publication Date
BRPI0820964A2 true BRPI0820964A2 (pt) 2015-07-14

Family

ID=40404481

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820964-2A BRPI0820964A2 (pt) 2007-12-11 2008-12-03 Oxazolidinonas para o tratamento e/ou profilaxia de insuficiência cardíaca

Country Status (18)

Country Link
US (1) US20110003804A1 (pt)
EP (1) EP2229173A1 (pt)
JP (1) JP2011506363A (pt)
KR (1) KR20110010689A (pt)
CN (1) CN101896185A (pt)
AU (1) AU2008335922A1 (pt)
BR (1) BRPI0820964A2 (pt)
CA (1) CA2708418C (pt)
DO (1) DOP2010000156A (pt)
IL (1) IL205675A (pt)
MA (1) MA31902B1 (pt)
MX (1) MX2010005545A (pt)
NZ (1) NZ586002A (pt)
RU (2) RU2494740C2 (pt)
SV (1) SV2010003578A (pt)
TN (1) TN2010000266A1 (pt)
UA (1) UA99638C2 (pt)
WO (1) WO2009074249A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012321A1 (en) * 2009-07-31 2011-02-03 Krka, D.D., Novo Mesto Processes for crystallization of rivaroxaban
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
ES2911600T3 (es) * 2017-06-20 2022-05-20 Inst Nat Sante Rech Med Métodos para identificar si pacientes con insuficiencia cardiaca aguda descompensada (ICAD) presentan un estado hipercoagulable
KR102715821B1 (ko) * 2017-11-09 2024-10-10 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 암 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약, 및 진단 방법
JP6574041B2 (ja) * 2017-12-15 2019-09-11 エルメッド株式会社 リバーロキサバン含有医薬組成物
JOP20200098A1 (ar) 2019-08-30 2021-02-28 Astrazeneca Ab طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667198B2 (en) * 1991-11-01 1996-03-14 Pharmacia & Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra

Also Published As

Publication number Publication date
KR20110010689A (ko) 2011-02-07
RU2010128442A (ru) 2012-01-20
WO2009074249A1 (en) 2009-06-18
CA2708418C (en) 2013-11-12
SV2010003578A (es) 2011-02-21
MA31902B1 (fr) 2010-12-01
US20110003804A1 (en) 2011-01-06
MX2010005545A (es) 2010-07-30
RU2494740C2 (ru) 2013-10-10
JP2011506363A (ja) 2011-03-03
EP2229173A1 (en) 2010-09-22
IL205675A0 (en) 2010-11-30
IL205675A (en) 2013-10-31
AU2008335922A1 (en) 2009-06-18
CN101896185A (zh) 2010-11-24
NZ586002A (en) 2012-06-29
CA2708418A1 (en) 2009-06-18
DOP2010000156A (es) 2011-02-15
RU2013134140A (ru) 2015-01-27
UA99638C2 (ru) 2012-09-10
TN2010000266A1 (en) 2011-11-11

Similar Documents

Publication Publication Date Title
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI1009034A2 (pt) composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada a mesma
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
BRPI0911923A2 (pt) dispositivos filamentosos para o tratamento de defeitos vasculares
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0911083A2 (pt) métodos para o tratamento ou prenvenção de diabetes mullitus e outros desequilíbrios metabólicos
PL3181134T3 (pl) Bifidobakterie do leczenia cukrzycy i stanów pokrewnych
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0915105A2 (pt) composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI0819105A2 (pt) composição para o tratamento e prevenção de edema de pálpebra
BRPI0906975A2 (pt) Escova de dente para o tratamento e/ou detecção de micróbios
BRPI0816836A2 (pt) Composições de limpeza e/ou tratamento
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
BR112012003372A2 (pt) vitamina d3 e análogos da mesma para o tratamento de alopecia.
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
BR112012004851A2 (pt) agente para o tratamento e/ou profilaxia de um distúrbio de humor, derivado de tiazol, e, uso do derivado de tiazol
BR112012000254A2 (pt) análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: JANSSEN PHARMACEUTICA N.V. (BE) , BAYER PHARMA AKT

B25A Requested transfer of rights approved

Owner name: JANSSEN PHARMACEUTICA N.V. (BE) , BAYER INTELLECTU

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.